Tratamentos de Digestive Health
Consulte os tratamentos de digestive health disponíveis. Todos incluem revisão por médico independente da UE, medicação genuína de farmácias licenciadas e entrega expresso discreta.
Digestive Health
Hyoscine Butylbromide (OTC)
Hyoscine butylbromide is an antispasmodic medication that relieves abdominal cramps and spasms. Particularly effective for irritable bowel syndrome (IBS), menstrual cramps, and other smooth muscle spasms in the gastrointestinal tract.
Lubiprostone (Amitiza)
Lubiprostone is a prescription medication for chronic constipation and irritable bowel syndrome with constipation (IBS-C). It works by increasing fluid secretion in the intestines to soften stool and promote bowel movements.
Omeprazole (OTC low-dose / Prescription high-dose)
Omeprazole is a proton pump inhibitor (PPI) that reduces stomach acid production. Effective for treating acid reflux, GERD, stomach ulcers, and other acid-related conditions. Low doses are available OTC, while higher doses require prescription.
Rifaximin (Xifaxanta)
Rifaximin is a non-absorbed antibiotic used to treat irritable bowel syndrome with diarrhea (IBS-D) and traveler's diarrhea. Because it stays in the gut, it has fewer systemic side effects than traditional antibiotics.
Semaglutide (Ozempic)
Semaglutide (brand name Ozempic) is a GLP-1 receptor agonist used for weight management and type 2 diabetes. It mimics the GLP-1 hormone to reduce appetite, slow digestion, and improve blood sugar control. Administered as a once-weekly injection.
Simethicone (OTC)
Simethicone is an anti-foaming agent that helps relieve gas, bloating, and pressure caused by excess gas in the digestive tract. Safe for most people including children and pregnant women.
Interested in Digestive Health?
Complete a confidential health assessment reviewed by an independent EU-registered doctor.
Start AssessmentDigestive health tratamentos in Europe
Gastrointestinal conditions affect a substantial proportion of the European population and account for a significant share of primary care consultations. Among the most prevalent are gastro-oesophageal reflux disease (GORD), peptic ulcer disease, and related acid-mediated conditions. It is estimated that GORD affects approximately 10–30% of the Western adult population, with heartburn and acid regurgitation being among the most commonly reported symptoms in primary care.
GORD occurs when stomach acid flows back into the oesophagus, causing inflammation, discomfort, and — in persistent cases — structural changes such as erosive oesophagitis or Barrett’s oesophagus. Risk factors include obesity, smoking, dietary factors, certain medications (particularly NSAIDs), and conditions that increase intra-abdominal pressure such as pregnancy.
Peptic ulcers — ulcerations in the stomach or duodenum — are most commonly caused by infection with Helicobacter pylori bacteria or long-term NSAID use. Management typically involves a combination of acid suppression and, where H. pylori is confirmed, antibiotic eradication therapy.
The mainstay of pharmacological tratamento for acid-related digestive conditions is the proton pump inhibitor (PPI) class, which includes omeprazole, lansoprazole, pantoprazole, and esomeprazole. PPIs provide potent and sustained acid suppression and are among the most widely prescribed medications in Europe. H2 receptor antagonists such as famotidine offer an alternative mechanism of acid reduction and remain in clinical use.
All tratamento decisions must be made by a qualified, independent médico based on thorough assessment of symptoms, duration, and relevant clinical history.
Available tratamentos
The following medications may be available for digestive health conditions through EU-registered médicos. This comparison is provided for informational purposes only.
| Medication | Active Ingredient | Class | Primary Indication |
|---|---|---|---|
| Omeprazole | Omeprazole | Proton pump inhibitor (PPI) | GORD, peptic ulcer, H. pylori eradication |
| Lansoprazole | Lansoprazole | Proton pump inhibitor (PPI) | GORD, peptic ulcer, H. pylori eradication |
| Famotidine | Famotidine | H2 receptor antagonist | GORD, peptic ulcer, heartburn |
Key distinctions:
- Omeprazole: The original PPI and a widely used reference standard. Generic formulations are broadly available and cost-effective. Effective for most acid-related conditions.
- Lansoprazole: A PPI with comparable efficacy to omeprazole. Some pacientes may experience improved tolerability or response with one PPI over another. Available in standard and orodispersible formulations.
- Famotidine: An H2 blocker with faster onset than PPIs (useful for on-demand use) but less sustained acid suppression. Suitable for milder symptoms or as an adjunct to PPI therapy in some cases.
Note on ranitidine: Ranitidine was withdrawn from EU markets in April 2020 following regulatory action by the EMA due to NDMA contamination concerns. It is no longer available in estados-membros da UE.
Como obter digestive health tratamento online
Prescrivia operates as a technology intermediary. We do not prescribe medications, employ médicos, or sell medicamentos. Our platform connects pacientes across Europe with independent EU-registered médicos and licensed pharmacies.
The process:
-
Complete uma avaliação de saúde — Answer a structured set of medical questions covering your symptoms, their duration and frequency, dietary and lifestyle factors, current medications (particularly NSAIDs), and any previous investigations such as endoscopy or H. pylori testing.
-
Independent médico review — An independent EU-registered médico reviews your assessment. If a receita médica digestive medication is clinically appropriate, the médico may issue a receita médica. If symptoms suggest the need for urgent investigation, the médico will advise accordingly.
-
Dispensa na farmácia — If a receita médica is issued, it is passed to a licensed EU farmácia partner. The farmácia dispenses the medication and arranges delivery to your address.
Important: A Prescrivia não garante that a receita médica will be issued. Prescribing decisions are made entirely by independent medical professionals.
How we compare
| Through Prescrivia | In-person GP appointment | |
|---|---|---|
| Availability | 24/7 online assessment | Subject to appointment availability |
| Wait time | Assessment reviewed within hours | Days to weeks depending on location |
| Travel required | No | Yes |
| Prescribing decision | Made by independent EU-registered médico | Made by your GP |
| Ongoing monitoring | Supported via follow-up assessments | Managed by your GP |
| Cost | Transparent pricing displayed upfront | Varies by country and healthcare system |
Note: Digestive symptoms that may indicate serious underlying pathology — including difficulty swallowing, unexplained weight loss, blood in stools, or new-onset symptoms in adults over 55 — require urgent in-person evaluation. Prescrivia’s platform is designed for adults with established, uncomplicated acid-related digestive conditions suitable for remote assessment.
Fontes
Medical information on this page is based on the following sources:
- Agência Europeia de Medicamentos (EMA). Omeprazole — Summary of Product Characteristics. Available at: ema.europa.eu
- Vakil N, et al. The Montreal definition and classification of gastroesophageal reflux disease. American Journal of Gastroenterology. 2006.
- Organização Mundial da Saúde (WHO). Gastrointestinal diseases — WHO data and statistics. who.int
This content is reviewed periodically to reflect updated clinical guidance. It is provided for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for advice relevant to your individual health circumstances.
Frequently asked questions
- Posso obter acid reflux or heartburn medication online na Europa?
- Yes. Through Prescrivia, you can complete a health assessment reviewed by an independent EU-registered médico. Where receita médica medication is clinically appropriate — for example, a proton pump inhibitor (PPI) for gastro-oesophageal reflux disease — the médico may issue a receita médica fulfilled by a licensed EU farmácia.
- O que é the difference between omeprazole and lansoprazole?
- Both are proton pump inhibitors (PPIs) that reduce stomach acid production by blocking the proton pump in gastric parietal cells. They have similar efficacy profiles for most indications. The choice between them depends on clinical factors, drug interactions, and individual paciente response, which the reviewing médico will assess.
- Is ranitidine still available in Europe?
- Ranitidine (an H2 receptor antagonist) was withdrawn from EU markets in 2020 following the discovery of unacceptable levels of NDMA (a probable carcinogen) in some formulations. Alternative H2 blockers such as famotidine remain available. A médico can advise on the most appropriate current tratamento options.
- How long can I take a proton pump inhibitor (PPI)?
- PPIs are highly effective for acute conditions and are often prescribed for 4–8 weeks for conditions such as peptic ulcers. Long-term or indefinite PPI use may be appropriate for conditions such as chronic GORD or Barrett's oesophagus, but carries risks including magnesium deficiency, Clostridium difficile infection, and potential reduced bone density. Long-term use should be reviewed regularly by a médico.
- What digestive symptoms require urgent in-person assessment rather than online tratamento?
- Symptoms including unexplained weight loss, difficulty swallowing (dysphagia), vomiting blood, black or tarry stools, persistent abdominal pain, or symptoms in pacientes over 55 with new-onset reflux warrant urgent in-person investigation to exclude serious conditions such as oesophageal or stomach cancer.
Pronto para começar?
Complete uma avaliação de saúde confidencial em cerca de 3 minutos.